Rybelsus Now First Line Therapy for Type 2 Diabetes
Rybelsus is a glucagon-like peptide-1 (GLP-1) receptor agonist medicine. To lower A1C, it enhances insulin synthesis (which lowers blood glucose) while inhibiting glucagon production (which raises blood glucose)
